Use of ketamine for the management of refractory status epilepticus in a dog

Journal of Veterinary Internal Medicine

Volumn 20, Issue 1, 2006, Pages 194-197

  Serrano, Sergi ^a   Hughes, Dez ^a   Chandler, Kate ^a  

^a QUEEN MOTHER HOSPITAL FOR ANIMALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; KETAMINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CASE REPORT; DOG; DOG DISEASE; EPILEPTIC STATE; MALE;

ANIMALS; DOG DISEASES; DOGS; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MALE; STATUS EPILEPTICUS;

CANIS FAMILIARIS;

EID: 32344452957     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2006)20[194:UOKFTM]2.0.CO;2     Document Type: Article

References (22)

1. Lowenstein D, Alldredge B. Status epilepticus. N Engl J Med 1998;338:970-976.
2. De Lorenzo R, Pellock J, Towne A, et al. Epidemiology of status epilepticus. J Clin Neurophysiol 1995;13:316-325.
3. Bateman S, Parent J. Clinical findings, treatment and outcome of dogs with status epilepticus or cluster seizures: 156 cases. JAVMA 1999;215:1463-1468.
4. Saito M, Muñana K, Sharp N, et al. Risk factors for development of status epilepticus in dogs with idiopathic epilepsy and effects of status epilepticus on outcome and survival time: 32 cases (1990-1996). J Am Vet Med Assoc 2001;219:618-623.
5. Rashkin M, Youngs C, Penovich P. Pentobarbital treatment of refractory status epilepticus. Neurology 1987;37:500-503.
6. Shaner D, MacCurdy S, Herring M, et al. Treatment of status epilepticus: A prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neurology 1988;38:202-207.
7. Avsar E, Empson R. Adenosine acting via A1 receptors, controls the transition to status epilepticus-like behaviour in an in vitro model of epilepsy. Neuropharmacology 2004;47:427-437.
8. Chandler K, Princivalle A, Fabian-Fine R, et al. Plasticity of GABA(B) receptor-mediated heterosynaptic interactions at mossy fibers after status epilepticus. J Neurosci 2003;23:11382-11391.
9. Nusser Z, Hajos N, Somogyi P, et al. Increased number of synaptic GABA(A) receptors underlies potentiation at hippocampal inhibitory synapses. Nature 1998;395:172-177.
10. Kapur J, Stringer J, Lothman E. Evidence that repetitive seizures in the hippocampus cause a lasting reduction of GABAergic inhibition. J Neurophysiol 1989;61:417-426.
11. +2 sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci 1997;17:7532-7540.
12. Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res 2000;42:117-122.
13. Mewashingh A, Sekhara T, Aeby A, et al. Oral ketamine in paediatric non-convulsive status epilepticus. Seizure 2003;12:483-489.
14. Sheth R, Gidal B. Refractory status epilepticus: response to ketamine. Neurology 1998;51:1765-1766.
15. Plumb D. Veterinary Drug Handbook, 3rd ed. Ames, IA: Iowa State University Press; 1999;362-365.
16. Kapur J, Lothman E. NMDA receptor activation mediates the loss of GABAergic inhibition induced by recurrent seizures. Epilepsy Res 1990;5.
17. Fujikawa D, Kim J, Daniels A. When and where does neuronal necrosis first appear in the lithium[sic]-pilocarpine seizure model? Epilepsia 1992:33(Suppl 3):36.
18. Fujikawa D. Neuroprotective effect of ketamine administered after status epilepticus onset. Epilepsia 1995;36:186-195.
19. Ubogu E, Sagar S, Lerner A, et al. Ketamine for refractory status epilepticus: A case of possible ketamine-induced neurotoxicity. Epilepsy Behav 2003;4:70-75.
20. Olney J. Excitatory transmitter neurotoxicity. Neurobiol Aging 1994;15:259-260.
21. Olney J, Labruyere J, Wang G, et al. NMDA antagonist neurotoxicity: Mechanism and prevention. Science 1991;254:1515-1518.
22. Sharp F, Jasper P, Hall J, et al. MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulated and retrosplenial neurons. Ann Neurol 1991;30:801-809.